In a sign of weak demand, Jazz Pharmaceuticals priced its offering of 6 million shares at $18, a 28% discount to its initially proposed $24-$26 range, which had been cut to $20-$21 earlier on Thursday. Jazz acquired two already approved drugs for the treatment ...read more
Jazz Pharmaceuticals, a developer of treatments for various neurological and psychiatric disorders, released the revised range on Thursday morning. Its anticipated IPO price is now $20-$21, down from its prior forecast of $24-$26, an 18% decline from the...read more
Jazz Pharmaceuticals, a specialty pharmaceutical company focused on neurological and psychiatric drugs, announced the terms of its IPO Thursday. The company plans to offer 6 million shares and expects the price per share to be between $24.00 and $26.00. ...read more
ALERT: Worst weekly perfomers: Jazz Pharmaceuticals, Virgin Mobile USA, Interactive Brokers
The following companies were the worst performing IPOs over the last five trading sessions: ...read more
Narcolepsy drug provider Jazz Pharmaceuticals prices 6mm shares below the range
In a sign of weak demand, Jazz Pharmaceuticals priced its offering of 6 million shares at $18, a 28% discount to its initially proposed $24-$26 range, which had been cut to $20-$21 earlier on Thursday. Jazz acquired two already approved drugs for the treatment ...read more
Jazz Pharmaceuticals lowers price range
Jazz Pharmaceuticals, a developer of treatments for various neurological and psychiatric disorders, released the revised range on Thursday morning. Its anticipated IPO price is now $20-$21, down from its prior forecast of $24-$26, an 18% decline from the...read more
Jazz Pharmaceuticals announces terms
Jazz Pharmaceuticals, a specialty pharmaceutical company focused on neurological and psychiatric drugs, announced the terms of its IPO Thursday. The company plans to offer 6 million shares and expects the price per share to be between $24.00 and $26.00. ...read more